LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Начало・Списък с акции・Fate Therapeutics Inc

Fate Therapeutics Inc

Затворен

СекторЗдравеопазване

1 -0.99

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

1.01

Ключови измерители
By Trading Economics
Приходи	1.8M -32M
Продажби	-166K 1.7M
EPS	-0.27
Марж на печалбата	-1,852.384
Служители	181
EBITDA	7.9M -29M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+400% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-4.6M 121M
Предишно отваряне	1.99
Предишно затваряне	1

Настроения в новините

By Acuity

55%

45%

305 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

0.9101 / 1.14 Подкрепа & съпротива

Fate Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.12.2025 г., 21:41 ч. UTC

Придобивния, сливания и поглъщания

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

26.12.2025 г., 20:22 ч. UTC

Пазарно говорене

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26.12.2025 г., 20:13 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26.12.2025 г., 19:24 ч. UTC

Придобивния, сливания и поглъщания

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26.12.2025 г., 17:45 ч. UTC

Пазарно говорене

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26.12.2025 г., 15:52 ч. UTC

Пазарно говорене

Oil Futures Turn Lower After Steady Start -- Market Talk

26.12.2025 г., 14:58 ч. UTC

Пазарно говорене

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26.12.2025 г., 14:41 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26.12.2025 г., 14:28 ч. UTC

Пазарно говорене

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26.12.2025 г., 13:47 ч. UTC

Пазарно говорене

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26.12.2025 г., 07:22 ч. UTC

Пазарно говорене

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26.12.2025 г., 05:03 ч. UTC

Пазарно говорене

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26.12.2025 г., 03:38 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

26.12.2025 г., 03:38 ч. UTC

Пазарно говорене

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26.12.2025 г., 02:44 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

26.12.2025 г., 02:44 ч. UTC

Пазарно говорене

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26.12.2025 г., 01:39 ч. UTC

Пазарно говорене

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26.12.2025 г., 01:14 ч. UTC

Пазарно говорене

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26.12.2025 г., 00:34 ч. UTC

Пазарно говорене

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26.12.2025 г., 00:15 ч. UTC

Пазарно говорене

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25.12.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25.12.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25.12.2025 г., 00:20 ч. UTC

Придобивния, сливания и поглъщания

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24.12.2025 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24.12.2025 г., 21:26 ч. UTC

Придобивния, сливания и поглъщания

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24.12.2025 г., 19:35 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

24.12.2025 г., 19:35 ч. UTC

Пазарно говорене

Treasury Yields Decline Ahead of Christmas -- Market Talk

24.12.2025 г., 19:09 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Global Equities Roundup: Market Talk

24.12.2025 г., 19:09 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24.12.2025 г., 19:06 ч. UTC

Пазарно говорене

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Fate Therapeutics Inc Прогноза

Ценова цел

By TipRanks

400% нагоре

12-месечна прогноза

Среден 5 USD 400%

Висок 8 USD

Нисък 2 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Fate Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Fate Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.9101 / 1.14Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Настроение

By Acuity

305 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.